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Abstract
Background: Three types of central venous access devices (CVADs)—peripherally inserted central catheters (PICCs),
skin-tunnelled central catheters (Hickman-type devices), and implantable chest wall Ports (Ports)—are routinely used in
the intravenous administration of anti-cancer treatment. These devices avoid the need for peripheral cannulation and
allow for home delivery of treatment. Assessments of these devices have tended to focus on medical and economic
factors, but there is increased interest in the importance of patient experiences and perspectives in this area. The aim
of this systematic review is to synthesise existing research regarding patient experiences of these CVADs to help
clinicians guide, prepare, and support patients receiving CVADs for the administration of anti-cancer treatment.
Method: A systematic search of MEDLINE, Embase, and CINAHL research databases will be carried out along with a
supplementary reference list search. This review will include quantitative, qualitative, and mixed methods studies
published in peer-review journals, reporting some aspect(s) of patient experiences or perspectives regarding the use of
PICC, Hickman, or Port CVADs for the administration of anti-cancer drugs. The methodological quality and risk of bias of
included papers will be assessed using the Mixed Methods Appraisal Tool (MMAT). Relevant outcome data will be
extracted from included studies and analysed using a thematic synthesis approach.
Discussion: The results section of the review will comprise thematic synthesis of quantitative studies, thematic
synthesis of qualitative studies, and the aggregation of the two. Results will aim to offer an account of current
understandings of patient experiences and perspective regarding PICC, Hickman-type, and Port devices in the context
of anti-cancer treatment. Confidence in cumulative evidence will be assessed using the Confidence in the Evidence
from Reviews of Qualitative research (CERQual) approach.
Systematic review registration: This systematic review protocol is registered with the International Prospective
Register of Systematic Reviews (PROSPERO). Registration number: CRD42017065851. This protocol was prepared
using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols checklist (PRISMA-P)
(Shamseer et al., BMJ 349: 2015).
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Background
Three types of central venous access devices (CVADs) are
routinely used in the intravenous administration of anti-
cancer treatment: peripherally inserted central catheters
(PICCs), skin-tunnelled central catheters (Hickman-type
devices), and implantable chest wall Ports (Ports).
All three deliver the drug into the superior vena cava,
which drains directly into the right atrium of the heart.
PICC lines are inserted into a peripheral vein in the arm.
The end of the line remains outside the body, emerging
from a point usually above the elbow. Hickman-type de-
vices are inserted into a central vein in the neck or
upper chest. The end of the line is tunnelled under the
skin to emerge from the chest, where it sits outside the
body. Chest wall Ports constitute a closed-system that is
fully implanted in the body with no external lines. Vas-
cular access is via needle puncture.
The main benefit of the devices is that they avoid the
need for peripheral cannulation which relies on peripheral
arm veins that easily become occluded. Moreover, periph-
eral cannulation usually involves repeated needle inser-
tions which patients tend to find unpleasant, even painful
and distressing [1]. They also allow for home delivery of
treatment via portable chemotherapy infusion pump.
Patient-centred approaches in the area of vascular ac-
cess exist but are limited. Published reports on the use
of vascular access devices in the context of anti-cancer
treatment have tended to focus on medical and eco-
nomic factors such as cost, maintenance, infection, and
other complications [2, 3], with much less attention
given to patient experiences and perspectives. It is there-
fore difficult to gain a clear picture of how patients ex-
perience PICC, Hickman, and Port devices [4].
Developing a better understanding of these experiences
would offer important insight into the roles these de-
vices play in patients’ quality of life and in the burden of
treatment. Moreover, a comparison of the effects and ex-
periences of these different devices would be important
in guiding device selection where more than one device
is clinically suitable.
To our knowledge no systematic review has previously
been carried out on this topic. The present review will
draw together existing approaches to recording and
assessing patient experiences of these CVADs in order
to produce a coherent understanding of such experi-
ences. This will help clinicians guide, prepare, and sup-
port patients receiving CVADs for the administration of
anti-cancer treatment.
Objectives
The aim of this review is to synthesise existing literature
that investigates patient experiences with PICC,
Hickman-type, and Port devices in the context of anti-
cancer treatment.
This review will address the following questions: What
are patients’ experiences and perspectives regarding the
three different central venous access devices implanted
for delivering long-term anti-cancer treatment: peripher-
ally inserted central catheters (PICC), Hickman-type
tunnelled catheters, and totally implanted chest wall
Ports? What effect (if any) do these CVADs have on pa-
tients’ quality of life in the context of anti-cancer treat-
ment, and what aspects of each device are important in
this respect? To what extent is it possible to compare
and contrast patient experiences of different CVADs?
What are the limitations of the existing literature, and
what additional research is needed?
Method
Eligibility criteria
This review will include empirical studies published in
peer-review journals meeting review-specific eligibility
criteria. These criteria were developed in line with the
existing search tools PICO (Population, Intervention,
Comparison, Outcome) [5] and SPIDER (Sample,
Phenomenon of Interest, Design, Evaluation, Research
type) [6]. PICO is typically used in systematic reviews of
quantitative research, answering clinical questions.
SPIDER was adapted from the former for use in system-
atic reviews of qualitative and mixed method research.
As our review will comprise quantitative, qualitative, and
mixed methods studies, our eligibility criteria include
elements from both.
As the use of PICCs and chest wall Ports in cancer
treatment was not well established until the 1990s and
involved a learning curve of several years, this review
will consider only studies published from the year 1997
onward.
Participant population
Studies will be eligible for inclusion where participants
are adult or paediatric patients (or parents/guardians of
paediatric patients) diagnosed with any type of cancer
including solid malignancy and haematologic malig-
nancy, who have received PICC, Hickman-type or chest
wall Port CVADs for the primary purpose of the admin-
istration of anti-cancer drugs.
Intervention
Included studies will involve the implantation (via any
technique) of any of the following venous access devices
for the long-term administration of any anti-cancer
treatment: (i) peripherally inserted central catheters
(PICC), (ii) subcutaneously tunnelled central catheters
(Hickman-type device), and (iii) implantable chest wall
Ports (Port).
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Comparator/control
Studies will not be included or excluded on the basis of
comparator. Where relevant and appropriate, compari-
sons between devices or other forms of venous access in
the administration of anti-cancer treatment will be con-
sidered in analysis.
Design
The review will include empirical studies using quantita-
tive and/or qualitative analytic methods. It will exclude
non-empirical studies but will not limit inclusion based
on study design. Studies that report outcomes regarding
CVADs but do not report or discuss any patient experi-
ence will also be excluded, as will studies that do not
provide sufficient detail for a thematic synthesis—i.e.
studies that do not contribute to themes or where data
cannot be themed.
Context
This review will include studies conducted in oncology
settings such as hospitals, and clinics, or related contexts
including home-treatment, patient care facilities, or pa-
tient groups/organisations.
Evaluation/outcomes
Finally, to be eligible for inclusion study, participants
must have completed a measure (e.g. questionnaire, sur-
vey) or provided an account (e.g. interview, focus group)
of some aspect of their own experience with or perspec-
tives on CVADs or in the case of paediatric patients,
where parents/guardians similarly report on some aspect
of their own and their children’s experiences and per-
spectives (please see ‘Outcomes and Prioritisation’
section, below, for explanations of these outcomes).
Information sources
A systematic search strategy will be used to search
MEDLINE, Embase, and CINAHL research databases. A
further important component of our search strategy, es-
pecially for the purposes of identifying relevant qualita-
tive research, involves forward and backward citation
tracking of publications meeting the inclusion criteria,
via Web of Science and Google Scholar. In addition, ex-
perts including authors of key papers will be contacted
to minimise the likelihood of overlooking key sources.
Search strategy
Search terms will target three key domains: (i) central
venous access devices, (ii) patient population, and (iii)
patient experiences. Search terms for Hickman and Port
devices and for cancer and chemotherapy will be
adapted from an existing systematic review comparing
the clinical effectiveness of these devices [7]. The search
strategy has been constructed with advice and guidance
from an information scientist. An example of search
terms and strategy is provided in Appendix.
Data management
Details of all searches will be recorded. Search results
will be downloaded to EndNote desktop software. Stud-
ies sourced through supplemental hand searching will be
recorded and imported into EndNote.
Selection process
Duplicate publications will be removed. The titles and
abstracts of all remaining publications will be assessed
against inclusion criteria. Those not meeting these cri-
teria will be excluded. All titles and abstracts identified
at this stage will also be screened independently by a
second reviewer. Disparities will be resolved through dis-
cussion or in consultation with a third party. Full texts
of the remaining publications will be obtained for fur-
ther review. Reasons for further exclusions at this stage
will be documented. The selection process, including
search results and reasons for exclusion at each stage of
screening, will be recorded and represented in a
PRISMA flow diagram (Additional file 1)[8].
Data collection process
Data extraction will be performed by one reviewer using
a data extraction form developed by the researchers for
the purposes of this review. This form will be refined by
the reviewer until the data extraction is complete, to en-
sure the appropriateness and usefulness of all fields.
Data items
For all studies, descriptive data will be extracted regard-
ing type(s) of vascular access device included in the
study, patient population, sample size, stated research
aims, study context, study design, methodology, reason
for measurement of patient experience, and timing of
measurement (in relation to device placement).
For quantitative studies, outcome data including de-
scriptive and inferential statistics will be extracted for
measures of patient experiences or perspectives regard-
ing CVADs. Details of measurement instruments will
also be recorded. The purpose of qualitative synthesis is
to ‘go beyond’ primary studies. This means the data to
be extracted from the qualitative studies comprises the
analyses and interpretations of the study authors includ-
ing all themes, categories, theories, models, and similar.
Therefore, all material labelled as results or findings by
the authors as well as subsequent discussions and con-
clusions relating to CVADs will be extracted in full [9].
Outcomes and prioritisation
The primary outcomes of interest will be any aspect of
patients’ (or parent/guardians’) self-reported experiences
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or perspectives relating to PICC, Hickman, or Port de-
vices. The data to be collected will include quantitative
and qualitative materials, i.e. survey or questionnaire
data, qualitative themes, and participant quotations.
For our present purposes, ‘patient perspectives’ will in-
clude opinions, attitudes, and evaluations (including ac-
ceptance and satisfaction). Patient experiences will
include emotions, physical sensations (e.g. pain, discom-
fort), psychological factors (e.g. stress, mood), and prag-
matic factors (e.g. routine activities).
Our analyses will prioritise any of the above as they re-
late to device acceptance or preference or to patient
wellbeing or quality of life. Secondary prioritisation will
be given to any of the above as they relate to device
placement (insertion).
Risk of bias in individual studies
Critical appraisal of methodological quality and risk of
bias of included papers will be undertaken independently
by two reviewers according to the Mixed Methods Ap-
praisal Tool (MMAT) developed by Pluye and colleagues
[10] for the appraisal of qualitative, quantitative, and
mixed methods research. Following these guidelines, the
reviewers will assess for all included studies whether (i)
there are clear research questions and (ii) the data col-
lected address the research question. The following as-
sessments will then be made, depending on study type:
Qualitative studies
The reviewers will assess the appropriateness of data
sources and analytical processes, the study’s consider-
ation of context/setting, and the study’s consideration of
researchers’ influence.
Randomised controlled trials
The reviewers will assess the study’s descriptions of ran-
domisation and allocation concealment, the complete-
ness of outcome data, and the level of drop-out rates.
Nonrandomised quantitative studies
The reviewers will assess the study’s minimisation of
selection bias, use of appropriate measurement instru-
ments, use of comparable groups across study condi-
tions, and the completeness of outcome data.
Descriptive cross-sectional quantitative studies
The reviewers will assess the appropriateness of the
study’s sampling strategy and the representativeness of
the sample, use of appropriate measurement instru-
ments, and acceptability of response rate.
Data analysis and synthesis
Data will be analysed using a narrative approach, specif-
ically thematic synthesis. Our analysis will comprise
three phases. The first phase will be a thematic synthesis
of the patient experience and perspective data extracted
from the quantitative studies selected for inclusion in
our review. We use inclusive definitions of patient ex-
perience and perspectives in this review. Our search
strategy therefore includes a range of broad search terms
relating to these phenomena. In addition, to our know-
ledge, there are no validated or standardised measures
relating to patient experiences of CVADs in common
usage. For instance, one such measure recently devel-
oped in France (specific to Port devices) [11] has to date
been used in a single pilot study [12]. Consequently, we
anticipate significant heterogeneity with regard to quan-
titative outcomes, and these data will not be quantita-
tively synthesised. The second phase of analysis will be a
thematic synthesis of the qualitative studies selected for
inclusion. The final third stage will be an aggregation of
both sets of analysis. In the interests of transparency, de-
tailed accounts of each stage of analysis will be recorded.
The second phase of analysis will be a thematic synthesis
of the patient experience and perspective data extracted
from qualitative studies selected for inclusion. The final
third stage will be an aggregation of both sets of analysis.
In the interests of transparency, detailed accounts of
each stage of analysis will be recorded.
Analytic method
Thematic synthesis is an adaptation for the purpose of
secondary data synthesis of ‘thematic analysis’ and pro-
vides a set of established methods and techniques for
the identification and development of analytic themes in
primary research data [9]. Thematic synthesis was se-
lected for the purposes of this review for a several rea-
sons [13]. First, it is well suited to our present objective
of aggregating existing evidence and identifying patterns
within data. Second, whilst it is most commonly associ-
ated with the synthesis of qualitative research outcomes,
thematic synthesis is also used for the synthesis of quan-
titative research outcomes, particularly where there is
heterogeneity in outcome variables and measurements.
Finally, the process of thematic synthesis offers good
transparency and outcomes are accessible.
Thematic synthesis involves three stages of analysis
(all three stages will be applied to all included quantita-
tive studies and repeated for all included qualitative
studies). First, the data—here, those pertaining to patient
experiences and perspectives—are coded. A coding
frame will be developed comprising codes derived from
the data. Coding will be carried out by the first reviewer
and checked by a second reviewer. Disparities or dis-
crepancies in coding will be resolved through discussion
or in consultation with a third party if necessary; the
coding frame will be adjusted accordingly.
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In the second stage of analysis, similarities between
codes will be identified. Codes will be grouped into ‘de-
scriptive themes’ that capture and describe patterns in
the data across studies. Each theme will be entered as
columns into a table, and coded data from each study
will illustrate the themes in rows, to facilitate compari-
son within and between studies, as part of the constant
comparison analytic process [14, 15]. Memos will be
used as part of the analysis process and may be included
in the summary table where clarity may be required
about the interpretation of a piece of evidence [16]. The
aim of this table is to demonstrate themes with illustra-
tive data and capture similarities and differences within
the data where possible—that is, to show how themes
are generated but also show divergence of findings in
each theme, where it applies.
The third stage of thematic synthesis will involve the de-
velopment of analytic themes. The purpose of this phase
of analysis is to ‘go beyond’ the primary reported data by
synthesising findings across studies and interpreting their
meaning in relation to our review research questions. This
will comprise the narrative component of our analysis,
which will provide narrative descriptions of each theme.
Once thematic synthesis has been completed for quanti-
tative studies and for qualitative studies, a final phase of
analysis will compare both sets of results, and the three
central venous access devices included in the review. This
process will aggregate results, providing an overall account
of current understandings of patient experiences and per-
spectives of CVADs in the context of anti-cancer treatment.
Confidence in cumulative evidence
Confidence in discrete review findings will be assessed
using the recently developed Confidence in the Evidence
from Reviews of Qualitative research (CERQual) ap-
proach [17]. Assessment of confidence in a given review
finding involves evaluating how likely it is that the find-
ing represents a real phenomenon, i.e. genuine patient
experiences of CVADs. This assessment will be based
upon an evaluation of the following: (i) methodological
limitations of the primary studies contributing to the
finding, (ii) the relevance of the primary contributing
studies with regard to the objectives of the systematic re-
view, (iii) the coherence of the finding, and (iv) the ad-
equacy of data supporting the finding.
For the purposes of this study, these evaluations will
be conducted as follows:
(i) Methodological limitations of contributing studies:
With reference to our prior critical appraisal of
methodological quality of these studies (see above),
we will evaluate the extent to which the primary
studies contributing to the finding are generally of
good methodological quality.
(ii) Relevance of contributing studies: We will evaluate
the extent to which the primary studies
contributing to the finding are similar in context
and aims/objectives to the present review. For
instance, studies carried out with the primary aim
of investigating some aspect of patients’ experiences
of CVADs in the context of cancer treatment will
be considered highly relevant. Those in which
findings relating to patient experiences of CVADs
are secondary or incidental to an alternative aim
will be considered to be of low relevance.
(iii)Coherence of finding: We will assess the extent to
which the finding offers a credible explanation for the
patterns it describes (e.g. tendencies, relationships
between relevant factors). This will involve assessing
the consistency or inconsistency of the pattern across
various research contexts represented by studies
included in the review and the ability of the finding
to account for notable variations across contexts.
Findings will be judged to be of low coherence if they
describe inconsistent or contradictory patterns and
where inconsistencies are unexplained.
(iv)Adequacy of supporting data: We will assess the
extent to which a given finding is supported by
substantial evidence defined both in terms of
number of studies contributing to a given study and
the quantitative robustness or qualitative richness
(i.e. fullness and depth) of the data provided by
these studies.
The above evaluations will necessarily entail subjective
judgements and will therefore be carried out by two re-
viewers working in collaboration. A summary table will
list for each review finding—primary contributing stud-
ies, evaluations of the above four domains, an overall
confidence rating (high, moderate, low, or very low), and
an explanation of the rating judgement.
Discussion
The results section of the review will summarise the
findings of (i) the thematic synthesis of quantitative
studies, (ii) the thematic synthesis of qualitative studies,
and (iii) the aggregation (comparison and juxtaposition)
of both sets of findings.
The results will offer an account of current under-
standings of patient experiences and perspective regard-
ing PICC, Hickman-type, and Port devices in the
context of anti-cancer treatment. They will explore the
extent to which and/or the ways in which these devices
affect patients’ quality of life. Comparisons between ex-
periences of different devices, or between especially
positive and negative experiences, will be explored as ap-
propriate and similarities and differences discussed and
tabulated, if the data lend themselves to this. Not all
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relevant comparisons can be identified in advance, so
other comparisons may become important. Finally, the
results of this review will consider the gaps in the exist-
ing literature and of ways in which existing data can be
used to support patients.
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Appendix
Search strategy
Ovid MEDLINE(R) via Ovid 1946 to Week 2 2017
1. exp Vascular Access Devices/
2. Catheterization, Central Venous/
3. (central venous adj5 (catheter* or access)).tw.
4. percutaneous catheter*.tw.
5. (venous adj5 (catheter* or access)).tw.
6. vascular access.tw.
7. hickman*.tw.
8. ((perhiperally adj5 catheter*) or PICC*).tw.
9. (implant* adj5 catheter*).tw.
10. (venous adj5 Port*).tw.
11. (Portacath* or Port-a-cath*).tw.
12. (implant* adj5 Port*).tw.
13. (implant* adj5 reservoir*).tw.
14. (subcutaneous* adj5 Port*).tw.
15. (tunnel* adj5 catheter*).tw.
16. or/1-15
17. exp Neoplasms/
18. chemotherapy.tw.
19. (tumor* or tumour*).tw.
20. cancer*.tw.
21. malignan*.tw.
22. oncolog*.tw.
23. or/17-22
24. exp Patient Satisfaction/
25. (patient* adj5 experience*).tw.
26. (patient* adj5 perspective*).tw.
27. (patient* adj5 view*).tw.
28. (patient* adj5 attitude*).tw.
29. (patient* adj5 opinion*).tw.
30. (patient* adj5 satisf*).tw.
31. (patient* adj5 accept*).tw.
32. (patient* adj5 evaluat*).tw.
33. (patient* adj5 assess*).tw.
34. (patient* adj5 choice*).tw.
35. (patient* adj5 decision*).tw.
36. (patient* adj5 prefer*).tw.
37. (patient* adj5 (questionnaire* or survey*)).tw.
38. or/24-37
39. 16 and 23 and 38
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